

TMB Substrate Set

Catalog# / Size	421101 / 110 ml x 2
Regulatory Status	RUO
Other Names	TMB Substrate
Description	The TMB Substrate Set contains 110 ml TMB Substrate A and 110 ml TMB Substrate B, sufficient for twenty 96-well plates. It is formulated with 3, 3', 5, 5' tetramethyl benzidine (TMB). The substrate can be catalyzed with peroxidase to produce a pale blue color which can be read spectrophotometrically at 370 or 620-650 nm. The TMB reaction may be stopped with BioLegend's Stop Solution (Cat. No. 423001), and read at 450 nm.

Product Details

Storage & Handling	The TMB Substrate Set (TMB Substrate A and TMB Substrate B) should be stored between 2°C and 8°C. Avoid prolonged exposure to light, contact with metal, air, or extreme temperatures.
Application	ELISA
Recommended Usage	TMB Substrate A should be clear and colorless. TMB Substrate B should be colorless to a very light amber. TMB Substrate is the mixture of equal volumes of TMB Substrate A with TMB Substrate B. For example, for one plate, mix 5.5 ml TMB Substrate A with 5.5 ml of TMB Substrate B in a clean container. Mix immediately before use. After mixing the reagents together, TMB substrate working solution should be colorless or very faint blue.
Application Notes	Warm to room temperature prior to use. To prepare a working solution, mix equal volumes of TMB Substrate A and TMB Substrate B. Prepare only the amount needed for each assay run. After wells are completely washed, to remove unbound antibody and HRP, add 100 µl to 200 µl substrate solution to each well. Discard any remaining working solution after use. For endpoint assays, add 50 µl to 100 µl of Stop Solution (2N H ₂ SO ₄ or 1M H ₃ PO ₄), which changes the color from blue to yellow. Read at 450 nm (minus 570 nm for wavelength correction) within 30 minutes of stopping the reaction. For kinetic assays, read the blue color at 620 - 650 nm.
Application References	<ol style="list-style-type: none">1. Kim MS, <i>et al.</i> 2008. <i>J Biochem.</i> 143:497. PubMed2. McNally A, <i>et al.</i> 2011. <i>PNAS.</i> 108:7529. PubMed3. Santiago FW, <i>et al.</i> 2012. <i>Vaccine.</i> 30:4606. PubMed4. Wan LY, <i>et al.</i> 2014. <i>Toxicol Sci.</i> PubMed5. de Pablo P, <i>et al.</i> 2014. <i>Ann Rheum Dis.</i> 73:580. PubMed
(PubMed link indicates BioLegend citation)	

Product Citations

1. Jameie F, *et al.* 2021. *Iran J Parasitol.* 1:16. [PubMed](#)
2. Vanderleyden I, *et al.* 2020. *Cell Rep.* 30:611. [PubMed](#)
3. Wenzek C, *et al.* 2022. *iScience.* 25:105540. [PubMed](#)
4. Bryant JD, *et al.* 2021. *Brain Behav Immun.* 97:204. [PubMed](#)
5. Jameie F, *et al.* 2020. *Arch Razi Inst.* 75:327. [PubMed](#)
6. Liu W, *et al.* 2016. *J Virol.* 90: 8496 - 8508. [PubMed](#)
7. Hsiue EH, *et al.* 2021. *Science.* 371:. [PubMed](#)
8. Peng L, *et al.* 2022. *Cell Rep.* 40:111160. [PubMed](#)
9. Fertey J, *et al.* 2021. *Methods Mol Biol.* 2414:97. [PubMed](#)
10. He Y, *et al.* 2021. *Bio Protoc.* 11:e3905. [PubMed](#)
11. Brooks JF, *et al.* 2020. *J Immunol.* 205:1239. [PubMed](#)
12. Brooks JF, *et al.* 2020. *Cytotherapy.* 22:436. [PubMed](#)
13. Stebegg M, *et al.* 2019. *Nat Commun.* 2.113194444. [PubMed](#)
14. Lee JL, *et al.* 2022. *Aging Cell.* 21:e13692. [PubMed](#)
15. Alapati T, *et al.* 2021. *Genes (Basel).* 13:. [PubMed](#)
16. Chang JH, *et al.* 2022. *Vaccines (Basel).* 10:. [PubMed](#)
17. Sari AN, *et al.* 2022. *Cancers (Basel).* 14:. [PubMed](#)
18. Walczewska M, *et al.* 2017. *Adv Exp Med Biol.* 10.1007/978-94-024-1079-2_41. [PubMed](#)
19. Sen K, *et al.* 2021. *Front Immunol.* 12:733539. [PubMed](#)
20. Han JP, *et al.* 2022. *Sci Adv.* 8:eabj6901. [PubMed](#)
21. Ding P, *et al.* 2022. *Cell Rep.* 39:110851. [PubMed](#)
22. Malik V, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)

23. Ramos-Pinto L, *et al.* 2021. *Animals (Basel)*. 11:. [PubMed](#)
24. Wu J, *et al.* 2020. *Immunity*. 53:115. [PubMed](#)
25. Nuvolone M, *et al.* 2017. *PLoS One*. 12:e0171923. [PubMed](#)
26. Qi T, *et al.* 2020. *Cell Rep*. 33:108452. [PubMed](#)
27. Oh E, *et al.* 2018. *Front Oncol*. 0.716666667. [PubMed](#)
28. Schwaderer J, *et al.* 2020. *Cell Death Dis*. 11:154. [PubMed](#)
29. Debernardi S, *et al.* 2020. *PLoS Med*. 17:e1003489. [PubMed](#)
30. Morgan S, *et al.* 2016. *J Immunol*. 196: 5014 - 5023. [PubMed](#)
31. Younis RH, *et al.* 2021. *Front Immunol*. 596646:12. [PubMed](#)
32. Fang Z, *et al.* 2022. *Nat Commun*. 13:3250. [PubMed](#)
33. Groeneveld D, *et al.* 2020. *J Hepatol*. 72:146. [PubMed](#)
34. Nogales A, *et al.* 2017. *Virology*. 500:1-10. [PubMed](#)
35. Wan L, *et al.* 2014. *Toxicol Sci*. 139:83. [PubMed](#)
36. Pagan JD, *et al.* 2018. *Cell*. 172:564. [PubMed](#)
37. Del Alcazar D, *et al.* 2019. *Cell Rep*. 28:3047. [PubMed](#)
38. Peng L, *et al.* 2022. *Cell Rep Med*. 3:100634. [PubMed](#)
39. Sun L, *et al.* 2021. *Sci Rep*. 11:12477. [PubMed](#)
40. Wu J, *et al.* 2021. *Nat Cell Biol*. 23:75. [PubMed](#)
41. Uematsu T, *et al.* 2016. *Sci Rep*. 6:37815. [PubMed](#)
42. Yang K, *et al.* 2020. *Cell Chem Biol*. 27:866. [PubMed](#)
43. Garg S, *et al.* 2019. *Biotechniques*. 67:166. [PubMed](#)
44. Falck-Jones S, *et al.* 2021. *J Clin Invest*. 131:. [PubMed](#)
45. Vijver SV, *et al.* 2021. *Front Immunol*. 12:733561. [PubMed](#)
46. Barbier M, *et al.* 2022. *Front Immunol*. 13:948431. [PubMed](#)
47. Surawut S, *et al.* 2017. *Sci Rep*. 7:40006. [PubMed](#)
48. McNally A, *et al.* 2011. *Proc Natl Acad Sci U S A*. 108:7529. [PubMed](#)
49. Kim M, *et al.* 2008. *J Biochem*. 143:497. [PubMed](#)
50. Strazza M, *et al.* 2022. *Mol Ther Methods Clin Dev*. 27:380. [PubMed](#)
51. Pedicone C, *et al.* 2022. *iScience*. 25:104170. [PubMed](#)
52. Phan TS, *et al.* 2021. *Sci Adv*. 7:. [PubMed](#)
53. Salehi S, *et al.* 2017. *PLoS One*. 10.1371/journal.pone.0163614. [PubMed](#)
54. Miller H, *et al.* 2021. *J Clin Microbiol*. 59:e0096421. [PubMed](#)
55. Leppkes M, *et al.* 2020. *EBioMedicine*. 58:102925. [PubMed](#)
56. Parrish H, *et al.* 2016. *Proc Natl Acad Sci U S A*. 113: 3000 - 3005. [PubMed](#)
57. Pablo P, *et al.* 2014. *Ann Rheum Dis*. 73:580. [PubMed](#)
58. Guo Y, *et al.* 2021. *Nat Commun*. 12:2623. [PubMed](#)
59. Reis B, *et al.* 2021. *Mar Drugs*. 19:. [PubMed](#)
60. Knopf J, *et al.* 2022. *Cells*. 11:. [PubMed](#)
61. Yang E, *et al.* 2015. *Acta Biochim Biophys Sin*. 47: 588-596. [PubMed](#)
62. Santiago F, *et al.* 2012. *Vaccine*. 30:4606. [PubMed](#)
63. Lee KS, *et al.* 2022. *iScience*. 25:105038. [PubMed](#)
64. Yang K, *et al.* 2021. *STAR Protoc*. 2:100288. [PubMed](#)

Antigen Details

Gene ID NA

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
 Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587